GeneLancet Biosciences’ platform addresses key challenges in CRISPR gene editing. Today, CRISPR-Cas9 gene editing utilizes single guide RNA (sgRNA). While sgRNA is effective in achieving consistent editing results, synthetic sgRNA suffers from low overall product purity (<50% LC-MS purity), which results in reduced editing efficiency and specificity. Fully-functional, truncated, lot-dependent impurities in sgRNA pose catastrophic risks to patients.
The crRNA in our ligated single-molecule guide RNA (LgRNA) is 32 nt long, and its high purity is readily accessible by routine purifications before ligation, which selects the full-length product of tracrRNA. All GeneLancet’s LgRNA products contain undetectable truncated spacer sequences and are ultra-pure (up to 99% by LC/MS) with very low levels of biologically active impurities. Our cutting-edge LgRNA technology in Doylestown, Pennsylvania, ensures these quality standards are consistently met to advance precise gene editing applications.
- GeneLancet’s LgRNA is highly pure, resulting in very high specificity
- LgRNA has high editing efficiency
- Production of LgRNA is robust, scalable, and highly cost-effective
- GeneLancet’s LgRNA platform is proprietary and intellectually distinct
Advancing Precision Medicine With Smarter RNA Tools
At GeneLancet Biosciences, we are constantly innovating to push the boundaries of genetic science. Our New-generation Guide RNA (LgRNA) Platform is a next-level solution designed to improve the specificity and efficiency of genome editing technologies. With its optimized structure and enhanced targeting ability, LgRNA plays a vital role in unlocking more effective, safer therapeutic interventions.
Why LgRNA Technology Changes the Game
Our New-generation Guide RNA (LgRNA) Platform offers a transformative approach for next-gen therapeutics by enhancing the precision and function of CRISPR-based tools. Designed with therapeutic applications in mind, this platform empowers researchers and biotech developers with greater flexibility, fewer off-target effects, and more robust outcomes. By integrating LgRNA into our solutions, GeneLancet Biosciences is helping redefine how gene-targeting therapies are developed and delivered.
- Increases gene-editing accuracy, reducing risks tied to off-target activity
- Improves the stability and efficiency of RNA molecules in complex therapeutic environments
- Enables more flexible designs for targeting a wider range of genetic mutations
- Supports scalable manufacturing, making it ideal for both early research and clinical deployment
- Unlocks potential for advanced treatments across rare diseases, cancer, and inherited disorders
GeneLancet Biosciences remains committed to leveraging cutting-edge platforms like LgRNA to bring forward the next generation of safe and targeted genetic therapies. With a strong focus on innovation and patient outcomes, our team is shaping the future of precision medicine through reliable and intelligent RNA solutions that drive real therapeutic impact.
Frequently Asked Questions
What is a next-gen guide RNA platform?
How is LgRNA different from regular guide RNA?
Is LgRNA safe to use in therapies?
Is using guide RNA safe for patients?
What kinds of conditions could be treated with guide RNA technology?
Take the First Step Toward Relief!
We’re here to support you every step of the way. Contact us today to learn how we can help you find relief and healing.